Merrimack Pharmaceuticals, Inc. (MACK)
(Delayed Data from NSDQ)
$5.90 USD
+0.05 (0.85%)
Updated May 3, 2019 03:59 PM ET
After-Market: $5.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.90 USD
+0.05 (0.85%)
Updated May 3, 2019 03:59 PM ET
After-Market: $5.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
by Zacks Equity Research
Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) announced third quarter results with loss narrower than expected, however, revenues misses the same.
What's in the Cards for Merrimack (MACK) in Q3 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Merrimack's (MACK) Reports Wider-than-Expected Q2 Loss
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) announced second-quarter results, reporting a wider than expected loss of 22 cents per share.
What's in the Cards for Merrimack (MACK) in Q2 Earnings?
by Zacks Equity Research
Sales of Merrimack Pharmaceuticals, Inc???s (MACK) only approved product, Onivyde to Ipsen is expected to bring in $450 million this quarter.
Merrimack Completes Enrollment in Phase II Study for MM-141
by Zacks Equity Research
Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.
Why Is Merrimack (MACK) Down 57.6% Since the Last Earnings Report?
by Zacks Equity Research
Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 22 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents. The company had reported a loss of 32 cents in the year-ago quarter.
Merrimack's (MACK) Reports Wider-than-Expected Q1 Loss
by Indrajit Bandyopadhyay
Merrimack reported a wider than expected first-quarter loss. The company reported a loss of 22 cents per share, wider than our consensus estimate of 7 cents.
What's in the Cards for Merrimack (MACK) in Q1 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations
Are Options Traders Betting on a Big Move in Merrimack (MACK) Stock?
by Zacks Equity Research
Options traders are pricing in a big move for Merrimack (MACK) shares as it has huge implied volatility.
Merrimack (MACK) Starts Enrollment in Solid Tumors Study
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) announced that it has enrolled the first patient in a phase I study on MM-310 for solid tumors.
Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 21 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate of a loss of 22 cents.
Merrimack's (MACK) Q4 Loss In-Line With Estimates
by Ekta Bagri
Merrimack (MACK) reported a fourth-quarter loss in-line with the estimates.
Merrimack (MACK): What Awaits the Stock in Q4 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.
Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?
by Zacks Equity Research
Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.
Is the Options Market Predicting a Spike in Merrimack (MACK) Stock?
by Zacks Equity Research
Options traders are pricing in a big move for Merrimack (MACK) shares as it has huge implied volatility.
Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) announced that it has entered into an agreement with Ipsen for $1.0 billion for Onivyde.
Merrimack (MACK) Drops as Breast Cancer Drug Trial Stops
by Zacks Equity Research
Shares of Merrimack Pharmaceuticals, Inc. (MACK) tanked 18.4% after the company announced the discontinuation of a phase II trial on its breast cancer candidate, MM-302.
How to Find Winning Biotech Stocks
by Tracey Ryniec
The biotechs are a gamble but here are some guidelines to lessen the risk.